METHOD FOR MANUFACTURING THERAPEUTIC IMMUNE CELLS

Tech ID: 33254 / UC Case 2023-065-0

INVENTION NOVELTY

Chimeric antigen receptor (CAR) T cells have so far shown limited efficacy on brain and solid tumors. UCSF investigators have developed a method of manufacturing recombinant immune cells by pre-treating them with a combination of small molecules to increase the number of CAR T cells in the tumor microenvironment and improve the survival of animal models bearing glioma in the brain relative to CAR T cells that have not received the pre-treatment. These results may be applicable to other solid tumors.

VALUE PROPOSITION

- Increased survival of CAR T cells following the intravenous infusion
- Improved survival of mice bearing brain tumors
- Manufacturing step can be easily incorporated into current manufacturing strategies for CAR T cells

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney

Gemma.Rooney@ucsf.edu

tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

CAR T, Solid tumors, Cell Manufacturing, Immune Cells, Glioma

CATEGORIZED AS

- Medical
  - Disease: Cancer
  - Therapeutics

RELATED CASES

2023-065-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco,CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax:

CONNECT

Follow Connect

© 2023, The Regents of the University of California

Terms of use Privacy Notice